Invention Grant
- Patent Title: Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
-
Application No.: US15070787Application Date: 2016-03-15
-
Publication No.: US09944918B2Publication Date: 2018-04-17
- Inventor: Charles P. Venditti , Randy J. Chandler
- Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Applicant Address: US DC Washington
- Assignee: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
- Current Assignee: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
- Current Assignee Address: US DC Washington
- Agency: Swanson & Bratschun, L.L.C.
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/04 ; C12N15/74 ; C12N9/90 ; A61K38/00

Abstract:
Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).
Public/Granted literature
- US20170067042A1 SYNTHETIC METHYLMALONYL-COA MUTASE TRANSGENE FOR THE TREATMENT OF MUT CLASS METHYLMALONIC ACIDEMIA (MMA) Public/Granted day:2017-03-09
Information query